Patrick Engelberts

1.3k citations
18 papers · 880 · h-index 10

Impact in

  • Genetics top 5%
    • Chronic Lymphocytic Leukemia Research
  • Immunology top 10%
    • Complement system in diseases
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses

Papers in

Co-authors
Paul W.H.I. Parren (10 shared papers)Frank J. Beurskens (7 shared papers)Ronald P. Taylor (4 shared papers)Janine Schuurman (6 shared papers)Margaret A. Lindorfer (3 shared papers)Paul V. Beum (2 shared papers)Aran F. Labrijn (3 shared papers)Esther C.W. Breij (7 shared papers)
Journals
The Journal of Immunology (3 papers)Molecular Cell (2 papers)Blood (2 papers)Cancers (1 paper)mAbs (1 paper)
Partner nations
NetherlandsUnited StatesDenmark

In The Last Decade

Patrick Engelberts

17 papers receiving 862 citations

Peers

Patrick Engelberts
Comparison fields: 5 of 70
  • Genetics 219
  • Immunology 412
  • Radiology, Nuclear Medicine and Imaging 414
  • Pathology and Forensic Medicine 204
  • Oncology 286
Replace Jantine E. Bakema with:
Jantine E. Bakema Netherlands
Steven L. Giardina United States
Franz Kricek Austria
Nathalie Y. Rosin United States
Jalal Khoshnoodi Iran
Sébastien Storck France
Marcia Stickler United States
Rajesh Vij United States
Athanasia Syrengelas United States
Paul Sims United States
Patrick Engelberts relative to Jantine E. Bakema Netherlands Jantine E. Bakema's profile →
Citations per field
00.5×2×3.5×
Jantine E. Bakema · 1×
Citations per year

Countries citing papers authored by Patrick Engelberts

Since Specialization
Citations

This map shows the geographic impact of Patrick Engelberts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Engelberts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Engelberts more than expected).

Fields of papers citing papers by Patrick Engelberts

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Engelberts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Engelberts. The network helps show where Patrick Engelberts may publish in the future.

Co-authors

The 25 scholars most cited alongside Patrick Engelberts, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Patrick Engelberts Line = papers co-authored together Patrick Engelberts links everyone, so they are left out of the graph.

All Works

18 of 18 papers shown
#Work
1
A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
PLoS Biology ·Rob N. de Jong, Frank J. Beurskens, Sandra Verploegen, Kristin Strumane, Muriel D. van Kampen, Marleen Voorhorst, Wendy Horstman, Patrick Engelberts, Simone C. Oostindie, Guanbo Wang, Albert J. R. Heck, Janine Schuurman, Paul W.H.I. Parren
2016153
2
Ibrutinib interferes with the cell-mediated anti-tumor activities of therapeutic CD20 antibodies: implications for combination therapy
Haematologica ·Fabio Da Roit, Patrick Engelberts, Ronald P. Taylor, Esther C.W. Breij, Giuseppe Gritti, Alessandro Rambaldi, Martino Introna, Paul W.H.I. Parren, Frank J. Beurskens, Josée Golay
2014120
3
Loss of CD20 and Bound CD20 Antibody from Opsonized B Cells Occurs More Rapidly Because of Trogocytosis Mediated by Fc Receptor-Expressing Effector Cells Than Direct Internalization by the B Cells
The Journal of Immunology ·Paul V. Beum, Elizabeth M. Peek, Margaret A. Lindorfer, Frank J. Beurskens, Patrick Engelberts, Paul W.H.I. Parren, Jan G. J. van de Winkel, Ronald P. Taylor
2011104
4
DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
EBioMedicine ·Patrick Engelberts, Ida H. Hiemstra, Bart de Jong, Danita H. Schuurhuis, Joyce Meesters, Irati Beltrán Hernández, Simone C. Oostindie, Joost Neijssen, Edward N. van den Brink, G. Jean Horbach, Sandra Verploegen, Aran F. Labrijn, Theodora W. Salcedo, Janine Schuurman, Paul W.H.I. Parren, Esther C.W. Breij
2020102
5
Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors
Cancers ·Jim Middelburg, Kristel Kemper, Patrick Engelberts, Aran F. Labrijn, Janine Schuurman, Thorbald van Hall
202199
6
Exhaustion of Cytotoxic Effector Systems May Limit Monoclonal Antibody-Based Immunotherapy in Cancer Patients
The Journal of Immunology ·Frank J. Beurskens, Margaret A. Lindorfer, Mohammed Farooqui, Paul V. Beum, Patrick Engelberts, Wendy J.M. Mackus, Paul W.H.I. Parren, Adrian Wiestner, Ronald P. Taylor
201296
7
Regulation of the Pap Epigenetic Switch by CpxAR
Molecular Cell ·Aaron D. Hernday, Bruce A. Braaten, Gina Broitman-Maduro, Patrick Engelberts, David A. Low
200470
8
Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation
mAbs ·Ewald TJ van den Bremer, Frank J. Beurskens, Marleen Voorhorst, Patrick Engelberts, Rob N. de Jong, Burt G van der Boom, Erika M. Cook, Margaret A. Lindorfer, Ronald P. Taylor, Patrick HC van Berkel, Paul W.H.I. Parren
201551
9
Type I CD20 Antibodies Recruit the B Cell Receptor for Complement-Dependent Lysis of Malignant B Cells
The Journal of Immunology ·Patrick Engelberts, Marleen Voorhorst, Janine Schuurman, Tom van Meerten, Joost M. Bakker, Tom Vink, Wendy J.M. Mackus, Esther C.W. Breij, Stefanie Derer, Thomas Valerius, Jan G. J. van de Winkel, Paul W.H.I. Parren, Frank J. Beurskens
201632
10
Regulation of the Pap Epigenetic Switch by CpxARPhosphorylated CpxR Inhibits Transition to the Phase ON State by Competition with Lrp
Molecular Cell ·Aaron D. Hernday, Bruce A. Braaten, Gina Broitman-Maduro, Patrick Engelberts, David A. Low
200424
11
A quantitative flow cytometric assay for determining binding characteristics of chimeric, humanized and human antibodies in whole blood: Proof of principle with rituximab and ofatumumab
Journal of Immunological Methods ·Patrick Engelberts, Carole Badoil, Frank J. Beurskens, Danièle Boulay-Moine, Karine Grivel, Paul W.H.I. Parren, Maxime Moulard
20128
12
Duobody-CD3xCD30 Demonstrates Potent Anti-Tumor Activity in Preclinical Models of CD30+ Hematologic Malignancies
Blood ·Simone C. Oostindie, Mir Farshid Alemdehy, Maarten L. Janmaat, Jenny Meerding, Kristel Kemper, Patrick Engelberts, Bart E.C.G. de Goeij, David Satijn, A. Kate Sasser, Esther C.W. Breij
20226
13
CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing
Communications Biology ·Chen‐Yi Liao, Patrick Engelberts, Andreea Ioan‐Facsinay, Janna E. Klip, Thomas Schmidt, Rob Ruijtenbeek, Erik H.J. Danen
20245
14
Studying the Effect of Different Macrostructures on in vitro Cell Behaviour and in vivo Bone Formation Using a Tissue Engineering Approach
Novartis Foundation symposium ·Robert J. Dekker, Clemens van Blitterswijk, Ingrid Hofland, Patrick Engelberts, J. Li, Joost D. de Bruijn
20034
15
Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models
Life Science Alliance ·Kristel Kemper, Ellis Gielen, Péter Boross, Mischa Houtkamp, Theo S. Plantinga, Stefanie AH de Poot, Saskia M. Burm, Maarten L. Janmaat, Louise A. Koopman, Edward N. van den Brink, Rik Rademaker, Dennis Verzijl, Patrick Engelberts, David Satijn, A. Kate Sasser, Esther C.W. Breij
20223
16
Duobody-CD3xCD20 Shows Unique and Potent Preclinical Anti-Tumor Activity in Vitro and In Vivo, and Is Being Evaluated Clinically in Patients with B-Cell Malignancies
Blood ·Ida H. Hiemstra, Patrick Engelberts, Bart de Jong, Danita H. Schuurhuis, Theodora W. Salcedo, Sandra Verploegen, Marten van der Zee, Arnout F. Gerritsen, Nedjad Losic, Sjeng Horbach, Roberto S Oliveri, Jeroen J. Lammerts van Bueren, Pernille A. Usher, Janine Schuurman, Paul W.H.I. Parren, Esther C.W. Breij
20182
17
PS1301 POTENT ANTI‐TUMOR ACTIVITY OF DUOBODY®‐CD3XCD20 IN PRECLINICAL MODELS IN VITRO AND IN VIVO
HemaSphere ·Ida H. Hiemstra, Patrick Engelberts, Bart de Jong, Danita H. Schuurhuis, Theodora W. Salcedo, Sandra Verploegen, M. van der Zee, P.A. Usher, Edward van den Brink, K. Sasser, Paul W.H.I. Parren, Aran F. Labrijn, Janine Schuurman, Esther C.W. Breij
20191
18
CD3xHER2 bsAb‐Mediated Activation of Resting T‐cells at HER2 Positive Tumor Clusters Is Sufficient to Trigger Bystander Eradication of Distant HER2 Negative Clusters Through IFNγ and TNFα
European Journal of Immunology ·Chen‐Yi Liao, Patrick Engelberts, Michiel van Dijk, A. Mieke Timmermans, John W. M. Martens, Elsa Neubert, Erik H.J. Danen
20250

About Patrick Engelberts

Patrick Engelberts is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology, Immunology, Genetics and Molecular Biology, having authored 18 papers that have together received 880 indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (14 papers), CAR-T cell therapy research (7 papers), Chronic Lymphocytic Leukemia Research (6 papers), Immunotherapy and Immune Responses (3 papers), Lymphoma Diagnosis and Treatment (2 papers), Epigenetics and DNA Methylation (2 papers), Glycosylation and Glycoproteins Research (2 papers) and T-cell and B-cell Immunology (2 papers). The work is most often cited by research in Genetics (219 citations), Immunology (412 citations), Radiology, Nuclear Medicine and Imaging (414 citations), Pathology and Forensic Medicine (204 citations) and Oncology (286 citations). Patrick Engelberts has collaborated with scholars based in Netherlands, United States and Denmark. Frequent co-authors include Paul W.H.I. Parren, Frank J. Beurskens, Ronald P. Taylor, Janine Schuurman, Margaret A. Lindorfer, Paul V. Beum, Aran F. Labrijn, Esther C.W. Breij, Aaron D. Hernday and Bruce A. Braaten. Their work appears in journals such as The Journal of Immunology, Molecular Cell, Blood, Cancers and mAbs.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jantine E. BakemaBreakdown of academic impact, for papers by Steven L. GiardinaBreakdown of academic impact, for papers by Franz KricekBreakdown of academic impact, for papers by Nathalie Y. RosinBreakdown of academic impact, for papers by Jalal KhoshnoodiBreakdown of academic impact, for papers by Sébastien StorckBreakdown of academic impact, for papers by Marcia SticklerBreakdown of academic impact, for papers by Rajesh VijBreakdown of academic impact, for papers by Athanasia SyrengelasBreakdown of academic impact, for papers by Paul Sims